Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Krystal Biotech Inc (NQ: KRYS )

118.77 +1.93 (+1.65%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 21, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 356,018
Open 115.08
Bid (Size) 110.00 (1)
Ask (Size) 190.12 (2)
Prev. Close 116.84
Today's Range 114.41 - 119.98
52wk Range 61.11 - 132.68
Shares Outstanding 22,205,642
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Have Million-Dollar Gene Therapies Finally Reached An Inflection Point?
Gene therapies are clearing the FDA and reaching seriously ill patients. They could cost millions. 
Via Investor's Business Daily
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2023
Via Benzinga

Performance

YTD
+49.91%
+49.91%
1 Month
-5.42%
-5.42%
3 Month
-1.03%
-1.03%
6 Month
+64.07%
+64.07%
1 Year
+69.04%
+69.04%

More News

Read More
5 Analysts Have This to Say About Krystal Biotech
Via Benzinga
Analyst Ratings for Krystal Biotech
Via Benzinga
Expert Ratings for Krystal Biotech
Via Benzinga
Krystal Biotech Sells Rare Pediatric Disease Priority Review Voucher For $100M
Via Benzinga
Why Krystal Biotech Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
What Will AbbVie Buy Next?
Via The Motley Fool
Krystal Biotech Inc. (NASDAQ: KRYS) is a Stock Spotlight on 6/8
Via Investor Brand Network
Up 48% in 2023, Is This Biotech Stock a Buy?
Via The Motley Fool
Why Shares of Krystal Biotech Are Rising Monday
Via The Motley Fool
3 Biotech Stocks to Buy Before the Breakout
Via InvestorPlace
2 Soaring Stocks With More Upside Potential
Via The Motley Fool
Arbutus Appoints Two New Executives
From Arbutus Biopharma Corporation
Via GlobeNewswire
Top 5 Health Care Stocks That Could Sink Your Portfolio This Quarter
Via Benzinga
Krystal Clear: Krystal Biotech Clears Resistance in Good Volume
Via MarketBeat
Exposures Product Safety
Analyst Expectations for Krystal Biotech's Future
Via Benzinga
Expert Ratings for Krystal Biotech
Via Benzinga
Option Care Health Selected by Krystal Biotech as Part of a Limited Distribution Specialty Pharmacy Network for VYJUVEK™
From Option Care Health, Inc.
Via GlobeNewswire
Unlocking a $750 Million Opportunity: Krystal Biotech's Vyjuvek and its Potent Impact on Dystrophic Epidermolysis Bullosa Treatment
Via Benzinga
Krystal Biotech Inc. (NASDAQ: KRYS) Highlighted for Surprising Price Action
Via Investor Brand Network
FDA Approves First Redosable Gene Therapy, Krystal Biotech's Treatment For Skin Blistering Disorder
Via Benzinga
NVIDIA To Rally Around 22%? Here Are 10 Other Analyst Forecasts For Monday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2023
Via Benzinga
Dentsply Sirona, Chico's FAS, Kontoor Brands And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.